Rhaponticum (Rhaponticum carthamoides): A Comprehensive Reference
1. Identity, Taxonomy, and Natural Source
Botanical name: Rhaponticum carthamoides (Willd.) Iljin. The plant was formerly classified under the synonym Leuzea carthamoides, and this name persists in older literature and in some Russian pharmacopoeial texts, where preparations are still labeled "leuzea." It is a perennial herb, commonly known as maral root or Russian leuzea, which has been used for centuries in eastern parts of Russia for its marked medicinal properties. The epithet "maral root" derives from local folklore: the first to notice the effects of R. carthamoides were Altai hunters, who observed Cervus elaphus sibiricus deer, also called maral deer, feeding on the roots of the herb; based on these observations, R. carthamoides was given its traditional name 'maral root.'
Taxonomy: The genus Rhaponticum (Asteraceae) includes 24 species worldwide. R. carthamoides is the most pharmacologically studied member of the genus. It belongs to the family Asteraceae and is a perennial herb, up to 150 cm high, endemic to the Altai and Saian Mountains of South Siberia, where it naturally occurs in the alpine and subalpine meadows at 1,200–2,300 m above sea level.
Conservation status and cultivation: R. carthamoides is a rare, pharmacopoeial, and medicinal plant, endemic to Siberia and endangered due to the massive collection of raw material from the natural habitat. An R. carthamoides plantation was recently established in Northern Poland. Composition and antioxidant activity were compared for R. carthamoides leaf extracts obtained from plants grown in two plantations: in Poland and in Russia, the latter having growing conditions similar to those in the natural habitat.
Parts used: The primary medicinal material is the rhizome and root, though recent research has also examined above-ground parts. Although root tissue is the well-known source of biologically active compounds, recent studies have focused on the above-ground part of the plant due to its easier accessibility.
Common forms and preparations: Nowadays, R. carthamoides is available on the market in many forms, such as dried root, milled plant, capsules, and tinctures. In Russia, a standardized pharmaceutical preparation is particularly well established: the liquid extract of rhizomes and roots of Rhaponticum carthamoides (EtOH 70%; 1:1) is available in Russia in pharmacies as an OTC preparation and recommended for internal administration at the dose of 20–30 drops, 2–3 times a day before meals. The recommended course of treatment is 30–40 days. The plant has also been incorporated into food products: Rhaponticum carthamoides extract has been included in popular Russian beverages such as "Baikal" and "Sayani."
2. Traditional and Historical Use
The first recorded information about the use of Rhaponticum carthamoides by the ethnic groups living in the Baikal region was documented by the traveler and ethnographer G. Potanin in 1881. The local inhabitants believed that this plant granted physical and sexual forces to men. The old-timer population of Siberia says about this plant that it "raises a man from fourteen diseases and refills him with youth."
Rhaponticum carthamoides (Willd) Iljin, commonly known as maral root or Russian leuzea, has been widely used in the traditional Siberian medicine, mostly to treat overstrain and common weakness after illnesses, as a stimulant, and a remedy against male sex dysfunction.
A decoction from rhizomes and roots has been used in traditional medicine as a stimulating and anti-fatigue agent for quick recovery after illnesses, against impotence. Traditional preparations included teas, decoctions, infusions, and alcoholic tinctures of the dried root and rhizome.
R. carthamoides has been recognized for its potential biological activities, and the genus Rhaponticum has a traditional use in Chinese medicine as well, where related species (R. uniflorum) have been used for clearing heat, detoxification, and immune support.
In the last century, the muscle- and strength-building qualities of R. carthamoides were thoroughly investigated in Russia, and various preparations have been commonly used by elite Soviet and Russian athletes in order to upgrade psychological and physical reserves which were exhausted by hard training. Brekhman and Dardymov (1969) classified R. carthamoides as an adaptogen, a term used by herbalists to refer to a natural herb product which increases the body's resistance to stresses such as trauma, anxiety, and bodily fatigue.
Rhizomes and roots of leuzea are approved in officinal medicine and were included in the 9th edition of the State Pharmacopoeia of the USSR in 1961. After more than 25 years of research and clinical studies, Rhaponticum carthamoides radix et rhizoma was added to the Official Russian Pharmacopoeia, which recommends "the herb for increasing work efficiency, athletic performance and recovery after muscular workloads."
Currently, extracts or individual compounds from roots and rhizomes are used for their adaptogenic and tonic properties in various dietary supplements or nutraceutical preparations to promote muscle growth, treat impotency, eliminate physical weakness and mental weariness, as well as for recovery after surgery, infectious disease, or chemical intoxication.
3. Phytochemical Composition and Key Constituents
Several different classes of compounds have been previously isolated from various parts of R. carthamoides, of which the main groups are steroids, particularly ecdysteroids, and phenolics (flavonoids and phenolic acids), accompanied by polyacetylenes, sesquiterpene lactones, triterpenoid glycosides, and terpenes (essential oil). A comprehensive review published in Phytochemistry (2009) catalogued over 120 chemical structures from the plant.
3.1 Phytoecdysteroids
Phytoecdysteroids are the pharmacologically primary and most extensively studied class of compounds in R. carthamoides. High-accumulating plant species (>1% dry weight), such as Rhaponticum carthamoides, are important sources of ecdysteroids — particularly 20-hydroxyecdysone (20E) — for physiological, biochemical, and pharmacological experimentation and, nowadays, also for conducting clinical trials.
The principal ecdysteroid is 20-hydroxyecdysone (20E), also designated beta-ecdysone, ecdysterone, beta-ecdysterone, crustecdysone, or BIO101 in clinical trial contexts. Its chemical name is 2β,3β,14α,20R,22R,25-hexahydroxy-5β-cholest-7-en-6-one (CAS 5289-74-7). Additional ecdysteroid constituents identified from the methanolic root extract include ajugasterone C, makisterone C, 24-epi-makisterone A, and 20-hydroxyecdysone itself. The complex of bioactive ecdysterones in R. carthamoides has sometimes been referred to as "levseins," comprising more than 10 ecdysterones including 20-beta-ecdysterone, makisterone C, 24-dehydromakisterone A, carthamosterone, polypodyne B, and ajugasterone C.
A 2023 phytochemical study confirmed the phytoecdysteroid profile of the rhizome/root extract by HPTLC: the method confirmed the presence of 20-hydroxyecdysone (20E), ponasterone A (PA), and turkesterone (TU) in the root/rhizome extract (RCE).
3.2 Phenolics: Flavonoids and Phenolic Acids
The principal bioactive constituents of this plant are ecdysteroids, flavonoids, and phenolic acids. Among the phenolic compounds, chlorogenic acid methyl ester, vanillic acid, and tachioside have been identified by chromatographic methods. Flavonoids present in the plant have been shown to exert antiplatelet activity in vitro (see Section 6).
3.3 Polyacetylenes
Four compounds, 20-hydroxyecdysone and three polyacetylenes (polyines), were isolated and identified from rhizomes with roots of Rhaponticum carthamoides. These polyacetylene derivatives are of interest for their potential bioactivity but have been less systematically studied than the ecdysteroids.
3.4 Essential Oil
R. carthamoides is not only a source of phytosteroids and flavonoids, but is also a source of essential oil. The volatile profile of the essential oil differs between wild and cultivated populations. Forty-six components were tentatively identified in R. carthamoides oil from the wild population, with β-selinene (4.77%), estragole (6.32%), D-carvone (6.37%), cyperene (8.78%), and ledene oxide (11.52%) being the major constituents. In the essential oil from cultivated R. carthamoides, twenty-three compounds were tentatively identified, with humulene (7.68%), β-elemene (10.76%), humulene-1,2-epoxide (11.55%), ledene oxide (13.50%), and δ-elemene (19.08%) predominating.
3.5 Other Compound Classes
The plant also contains sesquiterpene lactones, triterpenoid glycosides, and phytosterols such as β-sitosterol and stigmasterol, which have been quantified alongside ecdysteroids in recent HPLC-MS/MS analytical studies of dietary supplements.
4. Mechanisms of Action
4.1 Ecdysteroids and Mammalian Receptor Interactions
20-Hydroxyecdysone (ecdysterone or 20E) is a naturally occurring ecdysteroid hormone that controls the ecdysis (moulting) and metamorphosis of arthropods, making it one of the most common moulting hormones in insects. A phytoecdysteroid produced by and extracted from various plants, including Rhaponticum carthamoides, it is thought to function as a plant defense against herbivory that disrupts the reproduction of insect pests. In arthropods, 20-hydroxyecdysone acts through the ecdysone receptor. Although mammals (including humans) lack this receptor, 20-hydroxyecdysone nonetheless affects mammalian biological systems.
The leading proposed mechanisms of action in mammals include:
- Estrogen Receptor Beta (ERβ) activation: Studies have elucidated that the mechanism of action of 20-hydroxyecdysone on human muscle cells appears to involve relatively selective activation of estrogen receptor beta (ERβ), known to result in muscle hypertrophy. It has also been identified as a MAS1 agonist. Molecular dynamics simulations have further supported this: the simulations reveal that ecdysterone preferentially binds to ERβ, forming stable and compact complexes characterized by minimal per-residue fluctuations.
- MAS1 receptor agonism: The current hypothesis is that ecdysterone (20-hydroxyecdysone) and its structural analogs activate a ubiquitous receptor known as MAS1, a component of the renin-angiotensin system (RAS). Murine data suggest that the MAS1 receptor is involved in multiple vital body functions, including muscle hypertrophy and energy production.
- Stimulation of protein synthesis via PI3K/Akt pathway: Murine C2C12 myotubes and human primary myotubes elevated protein synthesis by up to 20% when treated with 20E. 20E-induced hypertrophy and protein synthesis were prevented by GPCR inhibitor in differentiating C2C12 myoblasts.
- Difference from androgenic steroids: Emerging evidence indicates that, unlike traditional anabolic steroids that act primarily via the Androgen Receptor (AR), ecdysterone's anabolic effects may be mediated through Estrogen Receptors (ERs), particularly ERβ. This distinction is pharmacologically important because it suggests that ecdysteroids do not suppress endogenous testosterone or bind classical androgen receptors at relevant concentrations.
4.2 Adaptogenic and Neuroendocrine Mechanisms
Various types of preparations, extracts, and individual compounds derived from this species have been found to possess a broad spectrum of pharmacological effects on several organs such as the brain, blood, cardiovascular and nervous systems, as well as on different biochemical processes and physiological functions including proteosynthesis, work capacity, reproduction, and sexual function.
4.3 Anti-Adipogenic and Metabolic Mechanisms
Previous studies reported that 20E possesses anabolic, neuroprotective, and antitumor effects, restores renal dysfunction, and decreases triglycerides. It has the potential to prevent adiposity, dyslipidemia, and hyperglycemia. In rodent research, the hepatic expression of key gluconeogenic enzymes (PEPCK and G6Pase) has been decreased, ameliorating the pathogenic role of the liver in diabetes in high-fat-fed mice.
5. Scientific Evidence by Area of Use
5.1 Physical Performance, Muscle Mass, and Adaptogenic Effects
Evidence level: Preliminary to moderate (preclinical strong; human evidence mixed and limited)
In vitro and animal data: Murine C2C12 myotubes and human primary myotubes elevated protein synthesis by up to 20% when treated with 20E. This was supported by an increase in grip strength of mice after in vivo administration of 20E, and the same effect was found when ecdysteroid-containing plant extract was used. In a rat study, ecdysterone (1 µM) induced a significant increase in myotube diameter, comparable to dihydrotestosterone (1 µM) and IGF-1. An in vivo study in male rats showed that ecdysterone treatment led to an increase in muscle fiber size, particularly a significant increase in the diameter of type IIb fibers; serum IGF-1 also increased. The strong hypertrophic effect on soleus muscle fiber size was even stronger than that of the test compounds metandienone (Dianabol) and estradiendione (Trenbolox), both anabolic androgenic steroids, administered at the same dose of 5 mg/kg body weight over 21 days.
A 2020 animal study (published in the Journal of the International Society of Sports Nutrition) specifically investigated R. carthamoides extract combined with resistance exercise in rats: when acutely administered and coupled with resistance exercise, Rhaponticum extract can increase muscle protein synthesis (MPS), and a synergistic effect could be expected when combined with Rhodiola rosea.
Human / clinical evidence: Soviet and Eastern European athlete studies conducted from the 1970s through the 1990s provided early, though methodologically limited, human data. One study, reported by Azizov and Seifulla (1997), examined the effect of 20-day administration of Leuzea extract on track and field runners (5,000 m and 10,000 m). Intensive cyclic physical activity induced a significant decrease of IgG and IgA in blood serum of the athletes; Leuzea extract contributed to the restoration of lowered IgG, IgA, and C3 concentration, and the working capacity of the athletes grew by 10–15% in this case.
A double-blind, randomized, placebo-controlled, crossover study examined the acute effects of an herbal supplement containing a 70:30 blend of Rhaponticum carthamoides extract and Rhodiola rosea extract. Thirty men (age 22.3 ± 4.1 years) volunteered; following familiarization, participants visited the laboratory on three separate occasions where they consumed one 350 mg dose, a 175 mg dose plus 175 mg maltodextrin, or a placebo.
For the key ecdysterone-specific human RCT by Isenmann et al. (2019), conducted as a 10-week randomized, double-blind trial in young men (n = 46) performing strength training: participants given two to eight capsules of ecdysterone (6 mg per capsule) combined with the amino acid leucine (100 mg per capsule) daily showed significant increases in muscle mass. In this double-blind study, athletes who actually took ecdysterone showed a significantly higher increase in maximum muscle strength after the 10-week study period. Importantly, the supplement used in this trial was a spinach-derived ecdysterone product co-administered with leucine, not a pure Rhaponticum extract, which limits direct attribution of results to R. carthamoides. Additionally, differences were observed only in the groups receiving high doses (48 mg/day) of ecdysterone; the contrasting observations compared with other studies can be attributed to the varying concentrations of ecdysterone and the co-administration of leucine.
A 2021 12-week randomized double-blind placebo-controlled trial using a spinach extract standardized to ecdysterone (n = 45 adults over age 50) showed significant between-group differences in isokinetic and isometric muscle strength measurements in favor of the supplement group.
A small-scale clinical study on fitness club participants was conducted with R. carthamoides liquid extract: the efficacy of the liquid extract of Rhaponticum carthamoides was investigated during systematic training in fitness clubs; healthy female volunteers (25–40 years old) were randomly assigned to experimental (12 persons) and control (8 persons) groups, with the experimental group receiving 4.3 mL of extract 20–30 minutes before training.
Overall assessment: Small human studies and some clinical trials have investigated Rhaponticum extracts for effects on muscle strength, endurance, and recovery, with mixed and mostly preliminary results. A systematic review (Parr et al., 2015) noted limited clinical evidence supporting ergogenic benefits and highlighted the need for larger, well-controlled trials. Systematic reviews and modern clinical trials are limited, and results in human populations remain inconclusive. While there is a scientific rationale and some preliminary evidence for Rhaponticum's use as an exercise aid, the quality and quantity of clinical data do not yet provide strong validation.
5.2 Metabolic Health: Glucose, Lipid Metabolism, and Anti-Adipogenic Effects
Evidence level: Preclinical (animal and cell-based); no adequately powered human trials
A 2014 comparative animal study (published in BMC Complementary Medicine and Therapies) tested R. carthamoides extract against extracts of Glycyrrhiza glabra and Punica granatum in a high-fat diet (HFD)-induced rat model of metabolic syndrome. Six-month-old male Wistar Albino Glaxo rats were subjected to eight weeks of a standard diet, HFD, or HFD in which the extracts were incorporated at 300 mg/kg/day; serum lipid profile, corticosterone and cytokine concentrations, glucose tolerance, systolic blood pressure, triacylglycerol accumulation, and PPARα DNA-binding activities were determined. An ERC supplement significantly reduced the weight of epididymal tissue (19.0%, p < 0.01) and basal serum glucose level (19.4%, p < 0.05). ERC improved glucose intolerance as well as dyslipidemia more efficiently than the comparator extracts. The lowering effects of ERC consumption on serum TNF-α level and its restoring effect on adrenal corticosterone level significantly exceeded improvements induced by the comparators. ERC intake also reduced triacylglycerol accumulation and increased PPARα DNA-binding activity in the liver more significantly than comparators.
A 2023 in vitro study examined the anti-adipogenic effects of R. carthamoides root/rhizome extract using human adipocytes (Simpson–Golabi–Behmel syndrome cells): the results revealed that RCE, 20E, and turkesterone significantly reduced lipid accumulation in human adipocytes, demonstrating anti-adipogenic activity. RCE, 20E, and TU significantly reduced lipid accumulation in human adipocytes, demonstrating their anti-adipogenic activity; moreover, RCE and 20E were found to effectively stimulate basal lipolysis. These are cell-based findings; human interventional data are not available.
5.3 Immunomodulatory Effects
Evidence level: Preclinical and limited human athlete data
The extracts and preparations from the plant exhibited various additional biological effects including antioxidant, immunomodulatory, anticancerogenic, antimicrobial, antiparasitic, and insect antifeedant or repellent activities. The reported biological activity of 20E includes immunomodulatory effects, anti-neoplastic activity, and neuroprotective, anti-fibrotic, wound-healing, and anti-inflammatory activities. Evidence in human populations remains limited to the athlete immune function study referenced above (restoration of suppressed IgG, IgA, and complement C3 in runners).
5.4 Antioxidant Activity
Evidence level: Preclinical (in vitro and animal)
Intake of R. carthamoides is associated with antioxidant activity among other properties. In vitro research has demonstrated the antioxidant effect of 20-hydroxyecdysone in model systems. These findings remain preclinical and have not been translated into controlled human antioxidant efficacy trials.
5.5 Neuroprotective and Central Nervous System Effects
Evidence level: Preclinical (animal and in vitro)
Intake of R. carthamoides extract is associated with neuroprotective activity. Preparations derived from this species have been found to possess pharmacological effects on the brain and nervous systems, as well as on different biochemical processes including work capacity. Animal studies and limited human reports (largely from Soviet-era research on cognitive performance and learning) underpin these claims; formal randomized clinical trials in human populations with neurological outcomes have not been published to date in major international peer-reviewed journals.
5.6 Reproductive Health and Sexual Function
Evidence level: Traditional and preclinical
Traditional use of R. carthamoides in Siberian medicine included use as a remedy against male sex dysfunction. Preparations derived from this species have been found to possess pharmacological effects on biochemical processes and physiological functions including reproduction and sexual function. Human clinical trial evidence in this domain is absent from peer-reviewed English-language literature.
5.7 Cardioprotective and Cardiovascular Effects
Evidence level: Preclinical
The extract has been evaluated for cardioprotective effects in preclinical models. In the metabolic syndrome rat study, EGG (licorice) extract reduced systolic blood pressure, whereas EGG but not ERC or EPG supplementation decreased systolic blood pressure by 12.0% (p < 0.05). Specific human cardiovascular outcomes data from controlled trials are not available.
5.8 Antiplatelet Activity
Evidence level: In vitro only
Research on the flavonoid fraction of R. carthamoides (Leuzea carthamoides) has demonstrated in vitro antiplatelet activity. A significant antiplatelet effect was identified from compounds isolated from rhizomes and roots of Rhaponticum carthamoides. This finding has not yet been evaluated in human trials.
6. Body Systems Associated with Rhaponticum
- Musculoskeletal system: Protein synthesis stimulation, muscle hypertrophy, anti-sarcopenic effects (primary area of research focus).
- Endocrine/metabolic system: Anti-diabetic effects, glucose metabolism, lipid metabolism, anti-adipogenic activity, and PPARα modulation (preclinical).
- Immune system: Immunomodulatory and anti-inflammatory activity; restoration of immunoglobulin levels suppressed by physical exertion (limited human data).
- Central nervous system: Adaptogenic, anti-fatigue, and neuroprotective effects; cognitive performance (mostly preclinical and historical human reports).
- Cardiovascular system: Cardioprotective and antiplatelet effects (in vitro and animal data).
- Reproductive system: Male sexual function and fertility support (traditional and preclinical).
7. Dosage Forms and Dosages Reported in Studies
The liquid extract of rhizomes and roots of Rhaponticum carthamoides (EtOH 70%; 1:1), as available in Russian pharmacies, is recommended for internal administration at the dose of 20–30 drops, 2–3 times a day before meals, with a recommended course of treatment of 30–40 days.
In the Isenmann et al. (2019) RCT, participants received two to eight capsules of ecdysterone (6 mg per capsule) combined with the amino acid leucine (100 mg per capsule) daily. The higher-dose group receiving 48 mg/day ecdysterone showed the most pronounced muscle mass differences from placebo.
In the fitness club clinical study, the experimental group received 4.3 mL of the R. carthamoides liquid extract 20–30 minutes before training.
In the metabolic syndrome rat model by Popa et al. (2014), ERC powder was incorporated into the diet at 300 mg/kg/day for eight weeks. (Note: animal doses are not directly translatable to human equivalent doses without pharmacokinetic adjustment.)
In the 2020 rat study examining R. carthamoides + Rhodiola rosea combined supplementation, the Rhaponticum hydro-alcoholic extract contained 20-hydroxyecdysone (20HE) at 0.4% and other phytoecdysteroids totaling 0.7%.
In the human crossover fatigability study, participants consumed either one 350 mg dose, a 175 mg dose of the Rhaponticum/Rhodiola supplement plus 175 mg of maltodextrin, or a placebo.
Among more than a dozen plant species containing ecdysterones, only Rhaponticum carthamoides extract has undergone complete human clinical trials and phytochemical research — though it must be noted that most of this research was conducted in Russia and Eastern Europe, often reported in Russian-language literature with variable methodological reporting standards by current international criteria.
8. Safety Considerations and Drug Interactions
8.1 Acute Toxicity
The acute toxic effects of Rhaponticum carthamoides liquid extract (1:1; 40% EtOH) were studied on male albino mice after intraperitoneal or subcutaneous injections. The extract did not produce mortality of animals at doses up to 40,000 mg/kg either 24 hours or 7 days after both injection routes. The corneal and pinna reflexes, irritability, and muscle tone of animals were not significantly affected by doses up to 5 g/kg. Injection of the extract at doses of 10–40 g/kg significantly reduced muscle tone and suppressed the corneal and pinna reflexes; abdominal spasms were observed in mice after intraperitoneal injection at all doses. These data indicate a very wide margin of safety at pharmacologically relevant doses in rodents.
8.2 Clinical Safety Reports
Trials for the safety of clinical application showed a remarkably high tolerance in humans. The intake of Rhaponticum carthamoides extract is reported in the reviewed literature not to be associated with side effects. However, this characterization is based on a relatively limited body of human data.
8.3 Pharmacopoeial Status and Regulatory Context
Unlike synthetic anabolic steroids, which are classified as controlled substances, ecdysteroids remain largely unregulated in many countries and are widely marketed as dietary supplements. Notably, ecdysterone has been included in the World Anti-Doping Agency (WADA) monitoring program, highlighting its potential impact on athletic performance and raising questions about its regulation. Supplementation with ecdysterone by professional athletes has raised concerns about its safety and quality, leading to its inclusion in the WADA monitoring program. As of the date of available evidence, ecdysterone is on the WADA monitoring list but has not been formally prohibited.
8.4 Potential Interactions and Precautions
R. carthamoides may increase the risk of bleeding, particularly in individuals with bleeding disorders or those taking anticoagulant or antiplatelet medications (e.g., warfarin, aspirin, clopidogrel). This concern is mechanistically consistent with the documented in vitro antiplatelet activity of the plant's flavonoid constituents.
Due to its potential stimulatory effects, R. carthamoides can interfere with sleep if taken close to bedtime.
Heavy metals are a documented concern for roots in general: research has found that R. carthamoides roots can accumulate toxic trace elements including Al, Cd, Ni, and Pb, reinforcing the importance of sourcing from regulated, quality-tested suppliers.
Populations with limited data: Safety data are absent for pregnant and lactating individuals. Individuals with hormone-sensitive conditions should exercise caution given the plant's ecdysteroid and phytosteroid content, though direct evidence of estrogenic harm in humans has not been established. Long-term safety data from rigorously designed human studies are not available, and it is considered important to continue non-clinical studies for better explanation of activity mechanisms and to perform additional clinical trials according to GCP procedures.
8.5 Product Quality and Variability
HPLC-MS/MS analyses of commercial dietary supplements purportedly containing R. carthamoides have revealed significant variation in actual ecdysteroid content relative to label claims. A 2025 study published in Food Analytical Methods developed and optimized analytical methods to determine 37 selected bioactive compounds in plant material and dietary supplements, underscoring that reliable standardization of commercial preparations remains an active area of analytical science.
9. Regulatory and Pharmacopoeial Recognition
Rhizomes and roots of leuzea are approved in officinal medicine and were included in the 9th edition of the State Pharmacopoeia of the USSR in 1961. Rhaponticum carthamoides is a popular plant in traditional and officinal medicine in Russia with a reputation as an evidence-based adaptogen. The plant is not included in the European Pharmacopoeia or in WHO herbal monographs. It does not appear in a Commission E monograph. It is classified as a dietary supplement ingredient in the United States and is not an approved drug by the FDA or EMA.
10. Current Research Directions
Processes have been developed to produce large amounts of pharmaceutical-grade 20E, and regulatory preclinical studies have assessed its lack of toxicity. The effects of 20E have been evaluated in early-stage clinical trials in healthy volunteers and in patients for the treatment of neuromuscular, cardio-metabolic, or respiratory diseases. The prospects and limitations of developing 20E as a drug are discussed, including the requirement for a better evaluation of its safety and pharmacological profile and for developing a production process compliant with pharmaceutical standards.
Current research investigates the beneficial biological effects of ecdysterone and related compounds in nutrition, highlighting roles not only in enhancing athletic performance but also in the management of various health problems. Plant-based diets associated with various health benefits often include sources rich in phytoecdysteroids. The therapeutic potential of phytoecdysteroid-rich extracts extends beyond sports nutrition, with promising applications in treating chronic fatigue, cardiovascular diseases, and neurodegenerative disorders.
References
Go back